Efficacy and safety of maribavir in Japanese patients with post-transplant cytomegalovirus infections: a phase III study.
Int J HematolJun 12, 2026 (epub)
Yoshinobu Kanda, Katsuto Takenaka, Tatsu Tanabe et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase III, multicenter study evaluated the efficacy and safety of maribavir in Japanese patients aged ≥16 years with cytomegalovirus (CMV) infections post-transplant. Among 41 patients treated, 68.3% achieved confirmed CMV viremia clearance at week 8, indicating maribavir's effectiveness in this population.
Key findings
- 68.3% of patients achieved confirmed CMV viremia clearance at week 8.
- 87.8% of patients experienced at least one treatment-emergent adverse event.
- The most common adverse events included nausea (24.2%) and anemia (17.1%).
Why it matters
The study highlights maribavir as a potential treatment option for CMV infections in transplant recipients, particularly for those resistant to standard therapies, addressing a significant clinical challenge in post-transplant care.